Racial disparities in the utilization of invasive neuromodulation devices for the treatment of drug‐resistant focal epilepsy
Epilepsia · 2024
DOI: 10.1111/epi.17961 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsia, 2024. Verfasst von Juan Luis Alcala-Zermeno und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy, Epilepsies, Partial, Healthcare Disparities. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Racial disparities affect multiple dimensions of epilepsy care including epilepsy surgery. This study aims to further explore these disparities by determining the utilization of invasive neuromodulation devices according to race and ethnicity in a multicenter study of patients living with focal drug‐resistant epilepsy (DRE). We performed a post hoc analysis of the Human Epilepsy Project 2 (HEP2) data. HEP2 is a prospective study of patients living with focal DRE involving 10 sites distributed across the United States. There were no statistical differences in the racial distribution of the study population compared to the US population using census data except for patients reporting more than one race. Of 154 patients enrolled in HEP2, 55 (36%) underwent invasive neuromodulation for DRE management at some point in the course of their epilepsy. Of those, 36 (71%) were patients who identified as White. Patients were significantly less likely to have a device if they identified solely as Black/African American than if they did not (odds ratio = .21, 95% confidence interval = .05–.96, p = .03). Invasive neuromodulation for management of DRE is underutilized in the Black/African American population, indicating a new facet of racial disparities in epilepsy care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
- Research and New Therapies, Epilepsy Foundation, Bowie, Maryland, USA.
- Department of Neurology, Comprehensive Epilepsy Center, NYU Langone Health, New York, New York, USA.
- Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
- Department of Neurology, Zucker Hofstra School of Medicine, Northwell Health, New York, New York, USA.
ORCID-Profile: Juan Luis Alcala-Zermeno, Brandy Fureman, Caitlin L Grzeskowiak, Ojas Potnis, Margaret W Logan, Daniel Friedman, Daniel Lowenstein, Ruben Kuzniecky, Jacqueline French
Zitieren
APA
Alcala-Zermeno, J. L., Fureman, B., Grzeskowiak, C. L., Potnis, O., Taveras, M., Logan, M. W., Rybacki, D., Friedman, D., Lowenstein, D., Kuzniecky, R., French, J., & HEP2 investigators (2024). Racial disparities in the utilization of invasive neuromodulation devices for the treatment of drug‐resistant focal epilepsy. Epilepsia. https://doi.org/10.1111/epi.17961
Vancouver
Alcala-Zermeno JL, Fureman B, Grzeskowiak CL, Potnis O, Taveras M, Logan MW, et al. Racial disparities in the utilization of invasive neuromodulation devices for the treatment of drug‐resistant focal epilepsy. Epilepsia. 2024. doi:10.1111/epi.17961
BibTeX
@article{AlcalaZermeno2024,
author = {Alcala-Zermeno, Juan Luis and Fureman, Brandy and Grzeskowiak, Caitlin L and Potnis, Ojas and Taveras, Maria and Logan, Margaret W and Rybacki, Delanie and Friedman, Daniel and Lowenstein, Daniel and Kuzniecky, Ruben and French, Jacqueline and HEP2 investigators, HEP2 investigators},
title = {Racial disparities in the utilization of invasive neuromodulation devices for the treatment of drug‐resistant focal epilepsy},
journal = {Epilepsia},
year = {2024},
doi = {10.1111/epi.17961}
}
EUVIMED